Trials / Completed
CompletedNCT02810600
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
Phase II Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,120 (actual)
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE injection in patients with suspected or diagnosed with tumors expressing somatostatin receptors. Each included patient will receive an administered dose of 50 mcg or less of the peptide (DOTA-TATE) and a range of activity between 100 - 200 MBq of 68Ga-DOTA-TATE. The efficacy of 68Ga-DOTA-TATE in assessing this kind of tumors has been proved by numerous studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Gallium-68 DOTA TATE PET scan | One PET/CT scan using Gallium-68 DOTA TATE |
Timeline
- Start date
- 2016-06-08
- Primary completion
- 2020-01-01
- Completion
- 2020-05-29
- First posted
- 2016-06-23
- Last updated
- 2021-05-18
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02810600. Inclusion in this directory is not an endorsement.